Key finding
The uMARS analysis showed a high rating (≥4 out of 5) of acT1ve by 80% of participants for both functionality and information.
This study evaluated the noninferiority of the acT1ve mobile health app for managing exercise in young people with Type 1 diabetes, finding similar rates of hypoglycemia before and during app use.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Quick read
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T1 Diabetes
Intervention
acT1ve mobile health app
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
Rate of level 1 hypoglycemia
Evidence
Moderate confidence
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the noninferiority of the acT1ve mobile health app for managing exercise in young people with Type 1 diabetes, finding similar rates of hypoglycemia before and during app use.
This study is significant as it suggests that mobile health apps like acT1ve can be safely integrated into the diabetes management routine of young individuals without increasing the risk of hypoglycemia. This could encourage more young people to engage in physical activity, which is crucial for their overall health and diabetes management.
Single-arm study design limits comparison with a control group. Findings may not be generalizable to all young people with Type 1 diabetes. Effectiveness measures were unclear, limiting definitive conclusions.
Published in
Publication details and source links for this paper.
Vinutha BS, Rachel L, Shaun T, et al. Noninferiority of a Mobile Health App for Exercise Management in Young People with Type 1 Diabetes: A Single-Arm Study. JMIR Diabetes. 2025;10:e68694. doi:10.2196/68694
Save this study and add notes to your research library.
Rate of level 1 hypoglycemia was 0.79 events per day preapp and 0.83 during app use, indicating no change.
Incidence of level 2 hypoglycemia was similar at 0.25 events per day preapp and 0.24 during app use.
Time spent <3.9 mmol/L was 0.71% preapp and 1.65% during app use, showing no significant difference.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) and Overall perceived quality of the acT1ve app, Percentage of time spent above 10.0 mmol/L, Percentage of time spent with sensor glucose levels <3.9 mmol/L, and 1 more.
This study contributes evidence to
Primary intervention
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital)
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
4
Evidence pairs
67
Related studies
Evidence topic
Contributes evidence
Core evidence
The primary outcomes reported in this study.
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) → Overall perceived quality of the acT1ve app
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) → Overall perceived quality of the acT1ve app
Evidence profile
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) → Percentage of time spent above 10.0 mmol/L
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) → Percentage of time spent above 10.0 mmol/L
Evidence profile
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) → Percentage of time spent with sensor glucose levels <3.9 mmol/L
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) → Percentage of time spent with sensor glucose levels <3.9 mmol/L
Evidence profile
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) → Severe hypoglycemia
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) → Severe hypoglycemia
Evidence profile
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) and Overall perceived quality of the acT1ve app.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies on GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital)
Contributes to GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) evidence base.
All studies measuring Overall perceived quality of the acT1ve app
Measures Overall perceived quality of the acT1ve app as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) appears to improve Overall perceived quality of the acT1ve app.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Overall perceived quality of the acT1ve app
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) for Severe hypoglycemia.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
Severe hypoglycemia
EvidenceScore™ Limited | EvidenceScore™ 34.2 | neutral | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) for Percentage of time spent above 10.0 mmol/L.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of time spent above 10.0 mmol/L
EvidenceScore™ Limited | EvidenceScore™ 34.2 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of GDM-DH mobile app (Garbhakalin Diabetes athawa Madhumeha-Dhulikhel Hospital) for Percentage of time spent with sensor glucose levels <3.9 mmol/L.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of time spent with sensor glucose levels <3.9 mmol/L
EvidenceScore™ Limited | EvidenceScore™ 34.2 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
